stockrowHalozyme Therapeutics, Inc.
HALO Healthcare Biotechnology
Halozyme Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.4 billion, up 37.6% from fiscal 2024.
- Revenue
- +39.2%
- EPS
- +45.6%
- Free cash flow
- −58.6%
- Total debt
- +115.1%
Quarter to September 2026, against a year earlier
Follow HALO
Alert me
Halozyme Therapeutics, Inc. (HALO) Price to free cash flow
As of 5 November 2026, Halozyme Therapeutics, Inc. (HALO) trades at a price to free cash flow of 15.9×. Over the past ten years it has ranged from 0.0× (December 2020) to 130× (February 2021); the current reading is higher than 65% of that period. That is below the Biotechnology industry median of 24.8× and below the Healthcare sector median of 21.1×.
Price to free cash flow, daily
Embed this chart
Annual newest first
| Period | Price to free cash flow | Change |
|---|---|---|
| FY2025 | 12.5× | (3.35%) |
| FY2024 | 12.9× | (2.03%) |
| FY2023 | 13.2× | (54.23%) |
| FY2022 | 28.9× | 52.12% |
| FY2021 | 19.0× | (82.37%) |
| FY2020 | 108× | — |
| FY2019 | 0.0× | — |
| FY2018 | 0.0× | — |
| FY2017 | 20.8× | — |
| FY2016 | 0.0× | — |
Quarterly newest first
| Period | Price to free cash flow | Change |
|---|---|---|
| Sep 2026 | 14.2× | 24.56% |
| Jun 2026 | 11.4× | (0.45%) |
| Mar 2026 | 11.4× | (8.60%) |
| Dec 2025 | 12.5× | 7.66% |
| 43 more quarters | Free account |
Against its own ten years
Price to free cash flow against peers
| Company | Price to free cash flow |
|---|---|
| KYMR Kymera Therapeutics, Inc. compare | n/m |
| SMMT Summit Therapeutics PLC compare | n/m |
| BBIO BridgeBio Pharma, Inc. compare | n/m |
| EXEL Exelixis, Inc. compare | 14.8× |
| HALO Halozyme Therapeutics, Inc. | 15.9× |
| BMRN BioMarin Pharmaceutical Inc. compare | 20.0× |
| JAZZ Jazz Pharmaceuticals PLC compare | 22.2× |
| ASND Ascendis Pharma A/S compare | 42.1× |
| TECH Bio-Techne Corp compare | 43.1× |
| Biotechnology industry median | 24.8× |
| Healthcare sector median | 21.1× |
| Market median | 14.1× |
What Price to free cash flow is
Price to Free Cash Flow Ratio shows how much investors pay for each dollar of cash a company generates after its capital spending.
Stock Price ÷ ((Operating Cash Flow (TTM) + Property, Plant, Equipment Change (Net) (TTM) + Intangible Assets Change (Net) (TTM)) ÷ (Shares (Basic, Weighted) (latest quarter)))
More on HALO
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement